Verona Pharma PLC
VRNA104.770USD
+0.100+0.10%
Fechamento 07/15, 16:00（ET）Cotações atrasadas em 15 min
71.35BValor de mercado
PerdaP/L TTM
Mais detalhes de Verona Pharma PLC Empresa
Verona Pharma Plc is a United Kingdom-based biopharmaceutical company. The Company is focused on developing and commercializing therapeutics for the treatment of respiratory diseases with unmet medical needs. Its product candidate, ensifentrine, is an investigational, inhaled, small molecule and dual inhibitor of the enzyme’s phosphodiesterase 3 and 4 (PDE3 and PDE4) combining bronchodilator and non-steroidal anti-inflammatory activities in one compound. It is engaged in developing inhaled ensifentrine for the treatment of chronic obstructive pulmonary disease (COPD). The Company's two additional formulations of ensifentrine are in Phase II development for the treatment of COPD: dry powder inhaler (DPI) and pressurized metered-dose inhaler (pMDI). The Company's wholly owned subsidiary is Verona Pharma, Inc.
Informações da empresa
Código da empresaVRNA
Nome da EmpresaVerona Pharma PLC
Data de listagemMar 30, 2005
Fundado em2005
CEODr. David S. Zaccardelli, Pharm.D.
Número de funcionários209
Tipo de títulosDepository Receipt
Fim do ano fiscalMar 30
EndereçoRiverside
CidadeLONDON
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited Kingdom
Código postalSE1 2RE
Telefone442032834200
Sitehttps://www.veronapharma.com/
Código da empresaVRNA
Data de listagemMar 30, 2005
Fundado em2005
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
677.38K
-53.74%
Dr. David S. Zaccardelli, Pharm.D.
Dr. David S. Zaccardelli, Pharm.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
530.46K
+35.57%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
--
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Kathleen Rickard, M.D.
Dr. Kathleen Rickard, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Ms. Christina Ackermann
Ms. Christina Ackermann
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Dr. Martin William Edwards, M.D.
Dr. Martin William Edwards, M.D.
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Mr. Ben Harber
Mr. Ben Harber
Company Secretary
Company Secretary
--
--
Ver Mais
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Mark W. Hahn, CPA
Mr. Mark W. Hahn, CPA
Chief Financial Officer
Chief Financial Officer
677.38K
-53.74%
Dr. David S. Zaccardelli, Pharm.D.
Dr. David S. Zaccardelli, Pharm.D.
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
530.46K
+35.57%
Mr. Vikas Sinha, CPA
Mr. Vikas Sinha, CPA
Non-Executive Independent Director
Non-Executive Independent Director
74.44K
--
Dr. Mahendra G. Shah, Ph.D.
Dr. Mahendra G. Shah, Ph.D.
Non-Executive Independent Director
Non-Executive Independent Director
73.08K
+700.00%
Ms. Lisa Deschamps
Ms. Lisa Deschamps
Non-Executive Independent Director
Non-Executive Independent Director
70.32K
+700.00%
Mr. Michael Austwick
Mr. Michael Austwick
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: dom, 18 de mai
Atualizado em: dom, 18 de mai
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Perceptive Advisors LLC
7.71%
Janus Henderson Investors
6.48%
Darwin Global Management Ltd
4.61%
Frazier Life Sciences Management, L.P.
4.06%
Ali (Behbahani)
3.75%
Other
73.39%
Investidores
Investidores
Proporção
Perceptive Advisors LLC
7.71%
Janus Henderson Investors
6.48%
Darwin Global Management Ltd
4.61%
Frazier Life Sciences Management, L.P.
4.06%
Ali (Behbahani)
3.75%
Other
73.39%
Tipos de investidores
Investidores
Proporção
Investment Advisor/Hedge Fund
25.32%
Hedge Fund
23.50%
Investment Advisor
16.36%
Private Equity
12.00%
Individual Investor
10.67%
Venture Capital
5.02%
Research Firm
3.63%
Family Office
1.18%
Bank and Trust
0.26%
Other
2.06%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
405
82.30M
96.67%
-3.99M
2025Q1
406
83.91M
98.59%
+940.31K
2024Q4
326
71.46M
84.46%
-16.29M
2024Q3
290
72.06M
88.66%
-13.37M
2024Q2
265
71.81M
88.57%
-10.49M
2024Q1
244
72.12M
89.24%
-7.07M
2023Q4
230
69.67M
87.15%
-7.79M
2023Q3
210
67.04M
84.35%
-7.14M
2023Q2
205
65.57M
82.53%
-8.85M
2023Q1
188
68.22M
86.63%
-3.18M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
Perceptive Advisors LLC
6.56M
7.71%
+171.23K
+2.68%
Mar 31, 2025
Janus Henderson Investors
5.52M
6.48%
+3.85M
+230.91%
Mar 31, 2025
Darwin Global Management Ltd
3.92M
4.61%
+3.11M
+384.08%
Mar 31, 2025
Frazier Life Sciences Management, L.P.
3.46M
4.06%
+73.90K
+2.18%
Mar 31, 2025
Ali (Behbahani)
3.19M
3.75%
+3.19M
--
Jan 16, 2025
Eventide Asset Management, LLC
2.89M
3.4%
-238.69K
-7.62%
Mar 31, 2025
RTW Investments L.P.
2.85M
3.35%
+1.03M
+56.44%
Mar 31, 2025
New Enterprise Associates (NEA)
2.69M
3.16%
-1.40M
-34.18%
Mar 31, 2025
Summit Partners Public Asset Management, LLC
2.32M
2.73%
+421.09K
+22.14%
Mar 31, 2025
Wellington Management Company, LLP
2.13M
2.5%
-893.74K
-29.54%
Mar 31, 2025
Ver Mais
ETFs Relacionados
Atualizado em: dom, 6 de jul
Atualizado em: dom, 6 de jul
Nome
Proporção
ALPS Medical Breakthroughs ETF
5.89%
AdvisorShares Dorsey Wright ADR ETF
5.19%
First Trust IPOX Europe Equity Opportunities ETF
1.75%
ProShares Ultra Nasdaq Biotechnology
0.85%
First Trust International Equity Opportunities ETF
0.8%
Invesco Nasdaq Biotechnology ETF
0.72%
iShares Biotechnology ETF
0.44%
JPMorgan Healthcare Leaders ETF
0.43%
Even Herd Long Short ETF
0.32%
Goldman Sachs Innovate Equity ETF
0.16%
Ver Mais
ALPS Medical Breakthroughs ETF
Proporção5.89%
AdvisorShares Dorsey Wright ADR ETF
Proporção5.19%
First Trust IPOX Europe Equity Opportunities ETF
Proporção1.75%
ProShares Ultra Nasdaq Biotechnology
Proporção0.85%
First Trust International Equity Opportunities ETF
Proporção0.8%
Invesco Nasdaq Biotechnology ETF
Proporção0.72%
iShares Biotechnology ETF
Proporção0.44%
JPMorgan Healthcare Leaders ETF
Proporção0.43%
Even Herd Long Short ETF
Proporção0.32%
Goldman Sachs Innovate Equity ETF
Proporção0.16%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
